Skip to main content
. Author manuscript; available in PMC: 2018 Jul 10.
Published in final edited form as: Muscle Nerve. 2016 Jan 27;53(3):363–369. doi: 10.1002/mus.24769

Figure 1. Study Schema.

Figure 1

Following enrollment (Week -4), study participants were treated with escalating doses of pyridostigmine for a period of 4 weeks. Those who did not achieve MMS were randomized to receive prednisone or placebo in a double-blind manner (Stage 1). Outcomes were assessed at Week 16, following which those participants who had not yet achieved MMS were crossed over to receive open-label high-dose prednisone (Stage 2). MMS – minimal manifestation status; OL – open label; DB – double-blind. Inline graphic indicates in-person visit; Inline graphic indicates telephone visit.